The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients.
 
Ishwaria Mohan Subbiah
Research Funding - Abbvie (I); Amgen (I); Bayer (I); Berg Pharma (I); BioXCell (I); D3 Oncology Solutions (I); Fujifilm (I); GlaxoSmithKline (I); Incyte (I); Multivir (I); NanoCarrier (I); Northwest Biotherapeutics (I); Novartis (I); Pfizer (I); PharmaMar (I); Roche/Genentech (I)
 
Chad Tang
No Relationships to Disclose
 
Arvind Rao
No Relationships to Disclose
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Research Funding - 3-V Biosciences; Abbvie; Aileron Therapeutics; ARMO BioSciences; AstraZeneca; Celgene; DelMar Pharmaceuticals; eFFECTOR Therapeutics; EMD Serono; Fujifilm; Genmab; GlaxoSmithKline; Hutchison MediPharma; Incyte; Kolltan Pharmaceuticals; MedImmune; Millennium; Novartis; Regeneron; Strategia Therapeutics; Vegenics
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - EMD Serono; Millennium; Sarah Cannon Research Institute
 
Vivek Subbiah
Research Funding - Abbvie; Amgen; Bayer; Berg Pharma; BioXCell; D3 Oncology Solutions; Fujifilm; GlaxoSmithKline; Incyte; Multivir; NanoCarrier; Northwest Biotherapeutics; Novartis; Pfizer; PharmaMar; Roche/Genentech
 
Razelle Kurzrock
Leadership - RScueRx Inc
Stock and Other Ownership Interests - Actuate Therapeutics; RScueRx
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Janssen; Jubilant Biosys; NCCN; NXT Health Strategies; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; The Dedham Group; UCSD Genomics Program Talk
Consulting or Advisory Role - AACR; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom
Speakers' Bureau - Guardant Health
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; EMD Serono; EMD Serono & Quintiles; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Global Biomarkers Consortium; ICRP; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma
 
Daniel D. Karp
No Relationships to Disclose
 
David S. Hong
Research Funding - Amgen; AstraZeneca; Daiichi Sankyo; Eisai; Genentech; Lilly; Merck; Mirati Therapeutics; miRNA Therapeutics; Novartis; Pfizer
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics